PMV Pharmaceuticals, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $66.7M
- Price
- $1.25
- % Change (Daily % change from the live per-ticker quote feed.)
- 0.00%
- Volume
- 89.2K
About
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
Quick stats
Shares outstanding53.3M
Computed float43.6M
Float / shares81.7%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001699382
Websitehttps://www.pmvpharma.com
AI Summary
AI-generated1/5
majorbullishearnings
PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights
PMV Pharmaceuticals completed enrollment for the Phase 2 monotherapy portion of the PYNNACLE trial evaluating rezatapopt in platinum-resistant ovarian cancer, with an NDA submission now planned for the first quarter of 2027.
Financially, the company reported $79.4 million in cash, cash equivalents, and marketable securities as of June 30, 2026, providing an expected cash runway into the second quarter of 2027.
The net loss for the second quarter narrowed to $18.1 million from $21.2 million a year ago, driven by lower R&D expenses of $14.7 million compared to $18.4 million in the prior year.
Red flags
- Cash runway extends only into Q2 2027